Boston Scientific Corporation $BSX is Munro Partners’ 8th Largest Position

Munro Partners increased its holdings in Boston Scientific Corporation (NYSE:BSX) by 29.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 1,242,080 shares of the medical equipment provider’s stock after acquiring an additional 283,475 shares during the period. Boston Scientific makes up about 3.3% of Munro Partners’ holdings, making the stock its 8th largest holding. Munro Partners owned approximately 0.08% of Boston Scientific worth $121,264,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Brighton Jones LLC grew its position in Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares in the last quarter. Axiom Investors LLC DE boosted its stake in shares of Boston Scientific by 26.8% in the 1st quarter. Axiom Investors LLC DE now owns 4,759,258 shares of the medical equipment provider’s stock valued at $480,114,000 after buying an additional 1,006,828 shares during the period. Synovus Financial Corp increased its position in shares of Boston Scientific by 32.1% in the 1st quarter. Synovus Financial Corp now owns 23,049 shares of the medical equipment provider’s stock valued at $2,325,000 after purchasing an additional 5,602 shares during the last quarter. FORA Capital LLC purchased a new stake in shares of Boston Scientific during the 1st quarter worth $5,143,000. Finally, CreativeOne Wealth LLC increased its stake in Boston Scientific by 36.1% in the first quarter. CreativeOne Wealth LLC now owns 7,679 shares of the medical equipment provider’s stock valued at $775,000 after purchasing an additional 2,037 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BSX. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Evercore ISI reaffirmed an “outperform” rating on shares of Boston Scientific in a report on Wednesday, October 22nd. Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Finally, Cowen reiterated a “buy” rating on shares of Boston Scientific in a research note on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and a consensus price target of $124.85.

Insider Buying and Selling

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,739,678.74. The trade was a 21.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 143,095 shares of company stock worth $14,228,950 in the last ninety days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $96.05 on Wednesday. The stock has a market capitalization of $142.38 billion, a P/E ratio of 51.36, a PEG ratio of 1.94 and a beta of 0.67. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The business’s fifty day moving average price is $98.67 and its 200 day moving average price is $101.17.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.